EN DE
Watch Microbot Medical Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Microbot Medical Inc (MBOT) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Microbot Medical Inc stock $0.96, price $1.11, that is 13.5% below the price, quality 33 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MM Microbot Medical Inc logo Thin data Nov 9, 2026

Microbot Medical Inc

MBOT · US
Expensive, weak quality

Our calculation puts a fair price 13% below what the stock costs today.

Low debt
Mixed vs. peers (4/8)
Fair value $0.9605 · Overvalued
Quality 33/100
Weak Growth (revenue 5y −39.4 %/yr in USD)
Negative free cash flow
Narrow moat 3/100 · thin data
Thin data
⚠ Dilution
Watch Microbot Medical Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$8.95 $0.8300 Fair Value $0.9605 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range $0.8300 – $8.95 · fair‑value band $0.6375 – $1.20 · the $1.11 price screens above the $0.9605 fair value. As of Nov 9, 2026.

Follow Microbot Medical in your weekly email

Every Wednesday you see whether Microbot Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.

Show moreShow less

The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations.

It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.

The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts

Stock analysis

Microbot Medical Inc (MBOT) currently trades at $1.11, while our model-based Fair Value estimate is $0.9605, 13% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.6375 (bear) to $1.20 (bull), the price of $1.11 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Microbot Medical Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$13.1M in FY2025.

Key figures

Market cap $74.6M Micro · EPS (TTM) $−0.2500 · Return on equity −32.9% · Return on assets (EBIT) −107% (5-year average) · Operating margin −2,568% · Revenue (TTM) $346K · Free cash flow −$13.1M · Net cash $3.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −13%, MBOT screens cheaper than that median.

Fair Value models

Bear $0.6375 Fair Value $0.9605 Bull $1.20
Price $1.11 · Downside -13.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.7500 $1.13 $1.41 55
All 1 models by family
Asset-Based
NCAV (Graham) $0.7500 $1.13 $1.41 55

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 29
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−88.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−55.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−39.4%
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,041.9% (2010) → −31,384.6% (2015)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MBOT screens overvalued: fair value 13% below the price. Compare with Abbott Laboratories, →

Compare Microbot Medical Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −13.5% · Above median
Profitability
Return on assets −16.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.96× · Cheapest 25%
PEG 0.70× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)15 · sector 6
FUTURE (revenue growth)0 · sector 35
PAST (return on equity)0 · sector 17
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs MBOT
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs MBOT
DexCom, Inc DXCM $79.41 $87.35 +10% vs MBOT
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs MBOT
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs MBOT
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs MBOT
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs MBOT
Abbott Laboratories, ABT $109.93 $75.28 −32% vs MBOT
Medtronic plc MDT $101.80 $65.61 −36% vs MBOT
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs MBOT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Microbot Medical Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Microbot Medical Inc Fair Value". https://www.fairvalue-calculator.com/stock/MBOT

Frequently asked questions

Is Microbot Medical Inc (MBOT) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.9605 versus a price of $1.11, about 13% lower (overvalued).
What is the fair value of MBOT?
Our model-based fair value for Microbot Medical Inc is $0.9605 (as of Nov 9, 2026), built from audited fundamentals. The current price: $1.11.
What is the quality score of MBOT?
Microbot Medical Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Microbot Medical Inc (MBOT)?
Our model-based price target is the fair value of $0.9605 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario $0.6375, optimistic scenario $1.20. It is a calculation from audited fundamentals, not an analyst target.
What is the Microbot Medical Inc stock forecast for 2026?
Our models put fair value at $0.9605, about 13% lower versus a price of $1.11 (overvalued). Cautious scenario $0.6375, optimistic scenario $1.20. The calculation is refreshed regularly with new filings.
What is the revenue of Microbot Medical Inc (MBOT)?
Microbot Medical Inc reported trailing-twelve-month revenue of about $346K (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Microbot Medical Inc (MBOT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Microbot Medical Inc it is $0.9605 per share (as of Nov 9, 2026), against a price of $1.11. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Microbot Medical Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, MBOT trades above its calculated fair value: price $1.11, fair value $0.9605, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MBOT?
No. The price is what the market pays today ($1.11); the fair value is what the company's own numbers justify ($0.9605). For Microbot Medical Inc the two are $0.1495 per share apart. That gap is exactly why we show both numbers side by side.
How much is Microbot Medical Inc worth?
The market values Microbot Medical Inc at about $74.6M (market capitalisation, as of Nov 9, 2026). Per share that is $1.11; our models calculate a fair value of $0.9605 per share.
What do the bullish and bearish scenarios say about MBOT?
Our models span a range for Microbot Medical Inc: cautious scenario $0.6375, base $0.9605, optimistic $1.20 per share (as of Nov 9, 2026, price $1.11). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of MBOT?
The PEG ratio of Microbot Medical Inc is 0.70 (P/E divided by earnings growth, as of Nov 9, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Microbot Medical Inc (MBOT)?
Balance-sheet figures for Microbot Medical Inc (as of Nov 9, 2026): return on equity −32.9%. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is MBOT from its 52-week high?
Microbot Medical Inc trades at $1.11, about 61% below its 52-week high of $2.85 and 18% above the low of $0.9401 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9605 is for.
Which stocks are comparable to Microbot Medical Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Microbot Medical Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $1.11, calculated fair value $0.9605 (−13%), Quality Score 33/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MBOT calculated?
We run Microbot Medical Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.9605 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Microbot Medical Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Microbot Medical Inc (MBOT)?
The closing price on Nov 6, 2026 was $1.11. Our model-based fair value is $0.9605, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Microbot Medical Inc right now?
A fairly wide model range ($0.6375 to $1.20) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Microbot Medical Inc

How large is the market capitalisation of Microbot Medical Inc (MBOT)?
The market capitalisation of Microbot Medical Inc is $74.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Microbot Medical Inc (MBOT)?
Earnings per share at Microbot Medical Inc are $−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Microbot Medical Inc (MBOT)?
The return on equity (ROE) of Microbot Medical Inc is −32.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Microbot Medical Inc (MBOT)?
On an EBIT basis the return on assets of Microbot Medical Inc is −107% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Microbot Medical Inc (MBOT)?
The operating margin of Microbot Medical Inc is −2,568% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Microbot Medical Inc (MBOT) generate?
The free cash flow of Microbot Medical Inc is −$13.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Microbot Medical Inc (MBOT) hold?
Microbot Medical Inc holds more cash than debt, $3.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Microbot Medical Inc in the live analysis

One click puts Microbot Medical Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.